{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:17:27Z","timestamp":1792019847590,"version":"4.4.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ccl.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T19:32:16Z","timestamp":1637350336000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Pathobiology of Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"40","author":[{"given":"Sudarshan","family":"Rajagopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Rei A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2021.08.001_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/01.CIR.18.4.533","article-title":"The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects","volume":"18","author":"Heath","year":"1958","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/thx.45.6.442","article-title":"Clinical correlates of angiographically diagnosed idiopathic pulmonary hypertension","volume":"45","author":"Gray","year":"1990","journal-title":"Thorax"},{"key":"10.1016\/j.ccl.2021.08.001_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1164\/rccm.201507-1508LE","article-title":"Intrapulmonary bronchopulmonary anastomoses and plexiform lesions in idiopathic pulmonary arterial hypertension","volume":"193","author":"Galambos","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib5","doi-asserted-by":"crossref","first-page":"L65","DOI":"10.1152\/ajplung.00103.2019","article-title":"Synchrotron-based phase-contrast micro-CT as a tool for understanding pulmonary vascular pathobiology and the 3-D microanatomy of alveolar capillary dysplasia","volume":"318","author":"Norvik","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib6","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/j.jacc.2004.02.033","article-title":"Pathologic assessment of vasculopathies in pulmonary hypertension","volume":"43","author":"Pietra","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/rccm.201903-0656CI","article-title":"Beyond the lungs: systemic manifestations of pulmonary arterial hypertension","volume":"201","author":"Nickel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1152\/japplphysiol.01017.2004","article-title":"Comparative physiology of hypoxic pulmonary hypertension: historical clues from brisket disease","volume":"98","author":"Rhodes","year":"2005","journal-title":"J\u00a0Appl Physiol (1985)"},{"key":"10.1016\/j.ccl.2021.08.001_bib9","doi-asserted-by":"crossref","first-page":"L977","DOI":"10.1152\/ajplung.00362.2011","article-title":"A\u00a0brief overview of mouse models of pulmonary arterial hypertension: problems and prospects","volume":"302","author":"Gomez-Arroyo","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib10","doi-asserted-by":"crossref","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","article-title":"The monocrotaline model of pulmonary hypertension in perspective","volume":"302","author":"Gomez-Arroyo","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","author":"Steiner","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib12","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1165\/rcmb.2014-0488OC","article-title":"Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension","volume":"54","author":"Jiang","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ccl.2021.08.001_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/01.RES.0000200180.01710.e6","article-title":"Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension","volume":"98","author":"Teichert-Kuliszewska","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1096\/fj.04-3261fje","article-title":"Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells","volume":"19","author":"Sakao","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.ccl.2021.08.001_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/j.2040-4603.2011.tb00309.x","article-title":"Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension","volume":"1","author":"Xu","year":"2011","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib17","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1073\/pnas.0605080104","article-title":"Alterations of cellular bioenergetics in pulmonary artery endothelial cells","volume":"104","author":"Xu","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccl.2021.08.001_bib18","doi-asserted-by":"crossref","first-page":"L502","DOI":"10.1152\/ajplung.00150.2018","article-title":"A\u00a0pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017","volume":"315","author":"Kuebler","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/01.RES.0000204572.65400.a5","article-title":"Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications","volume":"98","author":"Michelakis","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/CIRCULATIONAHA.114.008750","article-title":"Endothelial-to-mesenchymal transition in pulmonary hypertension","volume":"131","author":"Ranchoux","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.celrep.2014.01.042","article-title":"Recapitulation of developing artery muscularization in pulmonary hypertension","volume":"6","author":"Sheikh","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.ccl.2021.08.001_bib22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.4049\/jimmunol.1900239","article-title":"Nonclassical monocytes sense hypoxia, regulate pulmonary vascular remodeling, and promote pulmonary hypertension","volume":"204","author":"Yu","year":"2020","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.ccl.2021.08.001_bib23","doi-asserted-by":"crossref","first-page":"e139067","DOI":"10.1172\/jci.insight.139067","article-title":"Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension","volume":"6","author":"Ntokou","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ccl.2021.08.001_bib24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/CIRCRESAHA.107.161059","article-title":"Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling","volume":"102","author":"El-Bizri","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/CIRCULATIONAHA.116.023171","article-title":"Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-1","volume":"134","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4049\/jimmunol.1303048","article-title":"Adventitial fibroblasts induce a distinct proinflammatory\/profibrotic macrophage phenotype in pulmonary hypertension","volume":"193","author":"El Kasmi","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ccl.2021.08.001_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-2143(98)90020-8","article-title":"Pulmonary hypertension and inflammation","volume":"132","author":"Tuder","year":"1998","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1183\/09031936.03.00038903","article-title":"Inflammation in pulmonary arterial hypertension","volume":"22","author":"Dorfmuller","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.001_bib29","first-page":"275","article-title":"Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension","volume":"144","author":"Tuder","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ccl.2021.08.001_bib30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1164\/rccm.200608-1189OC","article-title":"Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling","volume":"175","author":"Taraseviciene-Stewart","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib31","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3892\/mmr.2014.3106","article-title":"Regulatory T cells protect against hypoxia-induced pulmonary arterial hypertension in mice","volume":"11","author":"Chu","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ccl.2021.08.001_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajpath.2013.10.027","article-title":"CD4+ T cells and IFN-gamma are required for the development of Pneumocystis-associated pulmonary hypertension","volume":"184","author":"Swain","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ccl.2021.08.001_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib34","doi-asserted-by":"crossref","first-page":"6721531","DOI":"10.1155\/2019\/6721531","article-title":"T\u00a0cell-derived IL-17a induces vascular dysfunction via perivascular fibrosis formation and dysregulation of (.)NO\/cGMP signaling","volume":"2019","author":"Schuler","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ccl.2021.08.001_bib35","doi-asserted-by":"crossref","first-page":"e013111","DOI":"10.1161\/JAHA.119.013111","article-title":"Th2 CD4(+) T cells are necessary and sufficient for schistosoma-pulmonary hypertension","volume":"8","author":"Kumar","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ccl.2021.08.001_bib36","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20171767","article-title":"Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice","volume":"215","author":"Chen","year":"2018","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.20071008","article-title":"Pulmonary arterial remodeling induced by a Th2 immune response","volume":"205","author":"Daley","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib38","first-page":"1318","article-title":"Developmental origin of lung macrophage diversity","volume":"143","author":"Tan","year":"2016","journal-title":"Development"},{"key":"10.1016\/j.ccl.2021.08.001_bib39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1165\/rcmb.2017-0061OC","article-title":"Cell origin dictates programming of resident versus recruited macrophages during acute lung injury","volume":"57","author":"Mould","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ccl.2021.08.001_bib40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2014.11.023","article-title":"Environment drives selection and function of enhancers controlling tissue-specific macrophage identities","volume":"159","author":"Gosselin","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ccl.2021.08.001_bib41","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cell.2014.11.018","article-title":"Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment","volume":"159","author":"Lavin","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ccl.2021.08.001_bib42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/ATVBAHA.120.314639","article-title":"Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension","volume":"41","author":"Zawia","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ccl.2021.08.001_bib43","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2353\/ajpath.2006.050599","article-title":"Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte\/macrophage lineage","volume":"168","author":"Frid","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ccl.2021.08.001_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.33549\/physiolres.933187","article-title":"Depletion of alveolar macrophages attenuates hypoxic pulmonary hypertension but not hypoxia-induced increase in serum concentration of MCP-1","volume":"65","author":"Zaloudikova","year":"2016","journal-title":"Physiol Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/aid.2018.0132","article-title":"Monocyte and alveolar macrophage skewing is associated with the development of pulmonary arterial hypertension in a primate model of HIV infection","volume":"35","author":"Schweitzer","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ccl.2021.08.001_bib46","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.4049\/jimmunol.1601692","article-title":"A\u00a0time- and compartment-specific activation of lung macrophages in hypoxic pulmonary hypertension","volume":"198","author":"Pugliese","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ccl.2021.08.001_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1084\/jem.20111741","article-title":"Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension","volume":"211","author":"Sawada","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib48","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1152\/ajplung.00234.2019","article-title":"Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension","volume":"318","author":"Jalce","year":"2020","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib49","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1164\/rccm.201402-0322OC","article-title":"Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor\/CD74 complex","volume":"192","author":"Le Hiress","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1465-9921-15-47","article-title":"Inflammatory cytokines in pulmonary hypertension","volume":"15","author":"Groth","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/2045-8932.97609","article-title":"Mast cell number, phenotype, and function in human pulmonary arterial hypertension","volume":"2","author":"Farha","year":"2012","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ccl.2021.08.001_bib52","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1183\/09031936.00043310","article-title":"Mast cells promote lung vascular remodelling in pulmonary hypertension","volume":"37","author":"Hoffmann","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.001_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1378\/chest.11-0663","article-title":"Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension","volume":"141","author":"Bartelds","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ccl.2021.08.001_bib54","doi-asserted-by":"crossref","first-page":"L927","DOI":"10.1152\/ajplung.00049.2011","article-title":"Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension","volume":"301","author":"Weng","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1165\/rcmb.2008-0415OC","article-title":"Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling","volume":"41","author":"Medoff","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ccl.2021.08.001_bib56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/CIRCRESAHA.115.301130","article-title":"The metabolic theory of pulmonary arterial hypertension","volume":"115","author":"Paulin","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib57","doi-asserted-by":"crossref","first-page":"e123611","DOI":"10.1172\/jci.insight.123611","article-title":"Human PAH is characterized by a pattern of lipid-related insulin resistance","volume":"4","author":"Hemnes","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ccl.2021.08.001_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1086\/690554","article-title":"Plasma acylcarnitines are associated with pulmonary hypertension","volume":"7","author":"Luo","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ccl.2021.08.001_bib59","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/CIRCULATIONAHA.115.019351","article-title":"Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension","volume":"133","author":"Brittain","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jacc.2015.10.072","article-title":"Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension","volume":"67","author":"Lewis","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib61","doi-asserted-by":"crossref","first-page":"1801900","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update","volume":"53","author":"Vonk Noordegraaf","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.001_bib62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","article-title":"The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure","volume":"115","author":"Ryan","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib63","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00109-013-1059-4","article-title":"A\u00a0metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension","volume":"91","author":"Sutendra","year":"2013","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib64","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.201702-0425LE","article-title":"Right ventricle vasculature in human pulmonary hypertension assessed by stereology","volume":"196","author":"Graham","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1165\/rcmb.2018-0095OC","article-title":"Vascular adaptation of the right ventricle in experimental pulmonary hypertension","volume":"59","author":"Graham","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ccl.2021.08.001_bib66","doi-asserted-by":"crossref","first-page":"1801899","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.001_bib67","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1242\/dev.040584","article-title":"TGFbeta family signaling: novel insights in development and disease","volume":"136","author":"Wharton","year":"2009","journal-title":"Development"},{"key":"10.1016\/j.ccl.2021.08.001_bib68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib69","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ccl.2021.08.001_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"International","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.ccl.2021.08.001_bib71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2009.02.007","article-title":"TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases","volume":"9","author":"Upton","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ccl.2021.08.001_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib73","doi-asserted-by":"crossref","first-page":"eaaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib74","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","article-title":"Inflammation, growth factors, and pulmonary vascular remodeling","volume":"54","author":"Hassoun","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib75","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.001_bib76","doi-asserted-by":"crossref","first-page":"e003155","DOI":"10.1161\/CIRCGEN.120.003155","article-title":"Bayesian inference associates rare KDR Variants with specific phenotypes in pulmonary arterial hypertension","volume":"14","author":"Swietlik","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib77","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1172\/JCI35070","article-title":"Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents","volume":"119","author":"Izikki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccl.2021.08.001_bib78","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccl.2021.08.001_bib79","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib80","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200811-1682OC","article-title":"Role of epidermal growth factor inhibition in experimental pulmonary hypertension","volume":"181","author":"Dahal","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib81","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib82","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1164\/rccm.201202-0309OC","article-title":"A\u00a0critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents","volume":"186","author":"Tu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib83","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib85","doi-asserted-by":"crossref","first-page":"148","DOI":"10.7326\/M14-2700","article-title":"Vasodilator-responsive idiopathic pulmonary arterial hypertension: evidence for a new disease?","volume":"162","author":"Brittain","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2021.08.001_bib87","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy","volume":"76","author":"Rich","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib88","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib89","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib90","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib91","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2012.04246.x","article-title":"Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension","volume":"61","author":"Pogoriler","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ccl.2021.08.001_bib92","first-page":"H1186","article-title":"Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension","volume":"269","author":"Morrell","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib93","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension","volume":"186","author":"de Man","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib94","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/bph.14172","article-title":"GPCRs in pulmonary arterial hypertension: tipping the balance","volume":"175","author":"Iyinikkel","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ccl.2021.08.001_bib95","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.001_bib96","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0167-5699(92)90039-A","article-title":"Endothelial cell binding of NAP-1\/IL-8: role in neutrophil emigration","volume":"13","author":"Rot","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.ccl.2021.08.001_bib97","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-5699(93)90209-4","article-title":"Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes","volume":"14","author":"Tanaka","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.ccl.2021.08.001_bib98","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.hrtlng.2014.04.016","article-title":"Increased levels of plasma CXC-Chemokine Ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension","volume":"43","author":"Yang","year":"2014","journal-title":"Heart Lung"},{"key":"10.1016\/j.ccl.2021.08.001_bib99","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1253\/circj.68.227","article-title":"Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension","volume":"68","author":"Hashimoto","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.ccl.2021.08.001_bib100","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCRESAHA.114.302221","article-title":"Evidence for the involvement of type I interferon in pulmonary arterial hypertension: novelty and significance","volume":"114","author":"George","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib101","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1183\/09031936.00145013","article-title":"Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients","volume":"44","author":"Zabini","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.001_bib102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12931-016-0336-5","article-title":"CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"17","author":"Olsson","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.ccl.2021.08.001_bib103","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1164\/ajrccm.164.2.2006154","article-title":"Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension","volume":"164","author":"Kimura","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib104","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.0000139859.68513.FC","article-title":"Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells","volume":"110","author":"Damas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib105","doi-asserted-by":"crossref","first-page":"143428","DOI":"10.1155\/2012\/143428","article-title":"Circulating cytokines and growth factors in pediatric pulmonary hypertension","volume":"2012","author":"Duncan","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ccl.2021.08.001_bib106","doi-asserted-by":"crossref","first-page":"e0123709","DOI":"10.1371\/journal.pone.0123709","article-title":"Elevated plasma CXCL12\u03b1 is associated with a poorer prognosis in pulmonary arterial hypertension","volume":"10","author":"McCullagh","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ccl.2021.08.001_bib107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/09537104.2018.1457780","article-title":"Increased platelet content of SDF-1alpha is associated with worse prognosis in patients with pulmonary arterial hypertension","volume":"30","author":"Kazimierczyk","year":"2018","journal-title":"Platelets"},{"issue":"10","key":"10.1016\/j.ccl.2021.08.001_bib108","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/art.40534","article-title":"CCL 21 as a potential serum biomarker for pulmonary arterial hypertension in Systemic Sclerosis","volume":"70","author":"Hoffmann-Vold","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ccl.2021.08.001_bib109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00408-010-9232-9","article-title":"CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival","volume":"188","author":"Heresi","year":"2010","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.001_bib110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bph.14826","article-title":"The role of chemokines and chemokine receptors in pulmonary arterial hypertension","volume":"178","author":"Mamazhakypov","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ccl.2021.08.001_bib111","doi-asserted-by":"crossref","first-page":"C882","DOI":"10.1152\/ajpcell.1992.262.4.C882","article-title":"Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction","volume":"262","author":"Post","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ccl.2021.08.001_bib112","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1096\/fj.00-0649fje","article-title":"Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5","volume":"15","author":"Archer","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.ccl.2021.08.001_bib113","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1161\/CIRCULATIONAHA.105.609008","article-title":"An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension","volume":"113","author":"Bonnet","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa1211097","article-title":"A\u00a0novel channelopathy in pulmonary arterial hypertension","volume":"369","author":"Ma","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib115","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.115.020951","article-title":"potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension","volume":"133","author":"Antigny","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib116","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nm.3695","article-title":"Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension","volume":"20","author":"Savai","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib117","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00109-017-1619-0","article-title":"FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension","volume":"96","author":"Bourgeois","year":"2018","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib118","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1172\/JCI43382","article-title":"Disruption of PPARgamma\/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival","volume":"121","author":"Alastalo","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccl.2021.08.001_bib119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1164\/rccm.201604-0886PP","article-title":"Translational advances in the field of pulmonary hypertension. Translating MicroRNA biology in pulmonary hypertension. It will take more than \"miR\" words","volume":"195","author":"Chun","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.001_bib120","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacbts.2020.07.008","article-title":"Micro-RNA analysis in pulmonary arterial hypertension: current knowledge and challenges","volume":"5","author":"Santos-Ferreira","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ccl.2021.08.001_bib121","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1161\/CIRCULATIONAHA.120.047626","article-title":"Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension","volume":"142","author":"Omura","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.08.001_bib122","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1164\/rccm.201910-2041OC","article-title":"Long noncoding RNA TYKRIL plays a role in pulmonary hypertension via the p53-mediated regulation of PDGFRbeta","volume":"202","author":"Zehendner","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:53:13Z","timestamp":1760007193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865121000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0733865121000643"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2021.08.001","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pathobiology of Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}